MedPath

Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Phase 2
Terminated
Conditions
Cervical Cancer
Registration Number
NCT00030472
Lead Sponsor
Gynecologic Oncology Group
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness liposomal doxorubicin in treating patients who have persistent or recurrent cancer of the cervix.

Detailed Description

OBJECTIVES:

* Determine the antitumor activity of doxorubicin HCl liposome in patients with persistent or recurrent squamous cell carcinoma of the cervix.

* Determine the toxicity of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive doxorubicin HCl liposome IV over 1 hour on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 22-60 patients will be accrued for this study.

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (17)

Jonsson Comprehensive Cancer Center, UCLA

🇺🇸

Los Angeles, California, United States

Community Hospital of Los Gatos

🇺🇸

Los Gatos, California, United States

MBCCOP - Hawaii

🇺🇸

Honolulu, Hawaii, United States

Holden Comprehensive Cancer Center at University of Iowa

🇺🇸

Iowa City, Iowa, United States

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support

🇺🇸

Bethesda, Maryland, United States

Tufts - New England Medical Center

🇺🇸

Boston, Massachusetts, United States

Cooper University Hospital

🇺🇸

Camden, New Jersey, United States

Roswell Park Cancer Institute

🇺🇸

Buffalo, New York, United States

State University of New York Health Sciences Center - Stony Brook

🇺🇸

Stony Brook, New York, United States

Lineberger Comprehensive Cancer Center, UNC

🇺🇸

Chapel Hill, North Carolina, United States

Scroll for more (7 remaining)
Jonsson Comprehensive Cancer Center, UCLA
🇺🇸Los Angeles, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.